Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that Algernon has announced positive data showing the Company has met a co-primary endpoint in it’s Phase 2 proof of concept study evaluating Ifenprodil in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough.

Mr. Moreau explains to Proactive that the IPF data has shown 65% of patients had stable or improved forced vital capacity (FVC) over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%. FVC is the amount of air that can be forcibly exhaled from one’s lungs after taking the deepest breath possible.

The Company plans to release the entire data set in August and also intends to present the results at the International Colloquium on Lung and Airway Fibrosis in Iceland this October.